Evidence map›Paper›PMID 28094169›Full record

Trial reportSchizophrenia research2017

A 12-week randomized controlled trial of twice-daily intranasal oxytocin for social cognitive deficits in people with schizophrenia.

L Fredrik Jarskog, Cort A Pedersen, Jacqueline L Johnson, Robert M Hamer, Shane W Rau, Tonya Elliott, David L Penn

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Schizophrenia research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 3 pooled it
8.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Racial disparities and predictors of functioning in schizophrenia.The American journal of orthopsychiatry · 2023
    Article
  14. Review
  15. Oxytocin administration versus emotion training in healthy males: considerations for future research.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2022
    Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

L Fredrik JarskogDepartment of Psychiatry, CB#7160, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address: jarskog@med.unc.edu.
Cort A PedersenDepartment of Psychiatry, CB#7160, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Jacqueline L JohnsonDepartment of Psychiatry, CB#7160, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Biostatistics, CB#7420, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Robert M HamerDepartment of Psychiatry, CB#7160, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Biostatistics, CB#7420, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Shane W RauDepartment of Psychiatry, CB#7160, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Tonya ElliottDepartment of Psychiatry, CB#7160, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
David L PennDepartment of Psychiatry, CB#7160, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Psychology and Neuroscience, CB#3270, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Australian Catholic University, School of Psychology, Melbourne, VIC, Australia.
University of North Carolina at Chapel Hill · US

Funding

Oxytocin Treatment of Social Cognitive and Functional Deficits in SchizophreniaR01MH093529 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEDERSEN, CORT ANDREW, PENN, DAVID LEWIS · 2011 to 2013
$1.6M
NIMH NIH HHS R01 MH093529
6 · The paper itself

Abstract

Social cognition is impaired in people with schizophrenia and these deficits are strongly correlated with social functioning. Oxytocin is a hypothalamic peptide that contributes to maternal infant bonding and has diverse pro-social effects in adults. This study tested the hypothesis that 12weeks of intranasal oxytocin will improve social cognitive function in outpatients with schizophrenia and schizoaffective disorder. Sixty-eight eligible participants were randomized to oxytocin (24IU twice daily) or placebo. Social cognitive function was assessed using the Emotion Recognition-40, Brüne Theory of Mind, Reading the Mind in the Eyes test, Trustworthiness task and Ambiguous Intentions Hostility Questionnaire at baseline, 6weeks and 12weeks. In addition, social function was assessed using the Specific Levels of Functioning Scale and a role-play test, and psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS). Fifty-five participants completed the 12-week trial. The study found no evidence for a differential advantage of oxytocin over placebo on social cognition. Among secondary outcomes, there was a modest advantage for oxytocin over placebo on a component of social functioning, although there was also evidence that the placebo group outperformed the oxytocin group on the role-play task. No between-group differences emerged on measures of psychopathology in pre-specified comparisons, but oxytocin showed significant within-group reduction in PANSS negative symptoms and significant between-group improvement in negative symptoms in the schizophrenia subgroup. Further testing is needed to clarify whether oxytocin has therapeutic potential for social cognitive deficits and/or negative symptoms in people with schizophrenia.

Indexed as

Schizophrenic PsychologySocial BehaviorAdministration, IntranasalAdolescentAdultAgedCognition DisordersFemaleFollow-Up StudiesHumansMaleMiddle AgedNeuropsychological TestsOutcome Assessment, Health CareOxytocinPsychiatric Status Rating ScalesOxytocinNegative symptomsOxytocinPsychosisSchizoaffective disorderSchizophreniaSocial cognition

Identifiers

PMID28094169
PMCPMC5474129
OpenAlexW2577452335

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.